Dulaglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dulaglutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
157
Registered trials
134
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Dulaglutide can convert its Fc fusion protein profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dulaglutide (query alias: dulaglutide) |
|---|---|
| Modality / target | Fc fusion protein; GLP-1R; GLP-1R agonists |
| Highest global status | Approved |
| Originator | Eli Lilly & Co. |
| Active developers | Beijing SL Pharmaceutical Co., Ltd., Eli Lilly Nederland BV, Eli Lilly & Co. |
The MCP disease footprint includes Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07537088 | Phase 4 | Not yet recruiting | 468 | Urine Albumin-to-Creatinine Ratio（UACR） |
| NCT07619495 | Not Applicable | Completed | 120000 | Composite of all-cause mortality, myocardial infarction, or stroke. |
| ChiCTR2600123454 | Not Applicable | Not yet recruiting | 234 | UACR |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Phase 3; n=13299; evaluation: not stated. Reported fields: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 801 participants ; Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 862 participants ; -
1710-P: Fragility Fracture Risk among Patients with Type 2 Diabetes Initiating Treatment with GLP-1 Receptor Agonists vs. Sulfonylureas
Not Applicable; n=387102; evaluation: Positive. Reported fields: Fragility fracture(aged ≥65 years): HR = 0.9(95.0% CI, 0.86 - 0.94); Fragility fracture(aged ≥65 years): HR = 0.9(95.0% CI, 0.86 - 0.94)
1309-OR: Dementia Progression with GLP-1 Receptor Agonists in People with Type 2 Diabetes and Mild Cognitive Impairment: Retrospective Cohort Study
Not Applicable; n=1320; evaluation: Positive. Reported fields: Absolute risk difference: ARD = -4.9(95.0% CI, -9.4 to -0.4); Absolute risk difference: ARD = -4.9(95.0% CI, -9.4 to -0.4)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dulaglutide addresses Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-08-03 | Sumitomo Pharma Notice of conclusion of sales collaboration with Eli Lilly for GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos" | Approved | Financial terms not disclosed |
| 2021-10-04 | Eli Lilly and Cipla enter into a strategic partnership in India to enhance access to Lilly’s key diabetes products | Approved | Financial terms not disclosed |
| 2015-07-09 | Eli Lilly Japan and Sumitomo Dainippon Pharma signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos" | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Application of dulaglutide in polycystic ovarian syndrome”. The milestone feed surfaced a patent-application signal described as “Therapeutic uses of dulaglutide”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
